文摘
摘要目的:描述疾病的肌肉特定酪氨酸激酶(麝香)积极重症肌无力(MMG)怀孕期间和产后。
背景:麝香抗体的患者约占5 - 8%的MG病例。尽管MMG主要是育龄妇女,其疾病在怀孕期间和产后阶段并没有被很好的描述。
设计/方法:回顾性研究的女性患者的医疗记录MMG杜克MG诊所2003年之后。
结果:十MMG患者怀孕期间的MG发现共有14怀孕。初始MG发达在孕期或产后6个月内症状在6/10的病人。四个病人2怀孕,3人开发MG在第一次怀孕。在先前诊断病人,毫克增加5/8的怀孕症状。
四个病人需要救援与血浆置换治疗怀孕期间或静脉注射免疫球蛋白。一个病人剖腹产后14小时劳动由于交付过程的失败。没有其他怀孕或分娩的并发症,并在交付所有的宝宝都健康。四个8病人胸腺切除术在怀孕之前或之后有胸腺增生。
结论:non-MuSK毫克,MMG女性疾病也可能改善或恶化,或开发初始MG孕期或产后6个月内症状。在我们的病人中,4需要救援疗法;怀孕和分娩是不复杂,除了1 MG病人需要剖腹产交付过程的失败。需要进一步的研究来理解的机制和风险恶化的MMG MG孕期或产后。临床医师应注意的变化MG在怀孕期间和产后MG的表现在这些时间可以危及生命。
披露:原田博士没有披露。Bettin博士没有披露。Juel博士的机构已经接到PCORI研究支持。Juel博士的机构已经接到Alexion研究支持。桑德斯博士已经收到个人薪酬在500 - 4999美元的范围作为顾问一致的卫生服务。桑德斯博士已经收到个人补偿的范围0 - 499美元为Cabaletta生物担任顾问。桑德斯博士已经收到个人薪酬在500 - 4999美元的范围作为顾问Kashiv生物科学。桑德斯博士已经收到个人薪酬在5000 - 9999美元的范围为在科学咨询服务或数据安全监测委员会动量制药。桑德斯博士已经收到个人薪酬在5000 - 9999美元的范围为在科学咨询服务或数据安全监测委员会詹森RnD。桑德斯博士已经收到个人薪酬在500 - 4999美元的范围为在科学咨询服务或为赛诺菲-安万特数据安全监测委员会。 Dr. Sanders has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for VielaBio. Dr. Sanders has received publishing royalties from a publication relating to health care. An immediate family member of Dr. Hobson-Webb has received personal compensation for serving as an employee of G1 Therapeutics. Dr. Hobson-Webb has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wiley Publishing. The institution of Dr. Hobson-Webb has received research support from Sanofi Genzyme. Dr. Raja has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant Health. The institution of Dr. Raja has received research support from American Brain Foundation/Myasthenia Gravis Foundation of America Clinician Scientist Development Award. Dr. Massey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenix. Dr. Massey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Revance Therapeutics. Dr. Massey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Momenta. The institution of Dr. Massey has received research support from Revance .
